J&J's Remicade losing ground in Quebec health plan despite court victory - (Financial Post via NewsPoints Desk)

  • According to an analysis of data from the Régie de l’assurance maladie du Québec (RAMQ), Johnson & Johnson's Remicade has steadily lost market share among patients enrolled in the province's public drug program, as reported in the Financial Post.

  • RAMQ had stopped covering Remicade, also known as infliximab, for some new patients in February 2017, in favor of biosimilar versions, mainly Pfizer's Inflectra.

  • However, while a Quebec court earlier this year ordered it to resume coverage, this has not reversed Pfizer’s gains, the news source said. 

  • By August, 13.4% of 2164 patients were on Renflexis, Merck & Co.'s biosimilar version of Remicade, with the rest on Pfizer's biosimilar.

  • Biosimilar market share for infliximab rose to 11.4% in January 2019, from 0.7% in February 2017, according to the analysis of RAMQ data.

To read more NewsPoints articles, click here.